BofA Securities upgraded Core Labs from Underperform to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/30/2023 | $22.00 → $21.00 | Neutral → Sell | Citigroup |
| 4/18/2023 | $21.50 | Neutral → Underperform | BofA Securities |
| 1/9/2023 | Underperform → Neutral | BofA Securities | |
| 10/7/2022 | $24.00 → $17.00 | Sell → Neutral | Citigroup |
| 9/26/2022 | $20.00 | Equal-Weight → Underweight | Morgan Stanley |
| 4/18/2022 | $19.50 → $21.30 | Neutral → Underweight | Piper Sandler |
| 1/18/2022 | $32.00 → $30.00 | Equal-Weight | Morgan Stanley |
| 12/7/2021 | $34.00 → $32.00 | Equal-Weight | Morgan Stanley |
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)
FOURTH QUARTER REVENUE OF $129.2 MILLION, DOWN 4% SEQUENTIALLY AND UP SLIGHTLY YEAR-OVER-YEARFOURTH QUARTER OPERATING INCOME OF $14.2 MILLION; EX-ITEMS, $15.7 MILLION, DOWN 14% SEQUENTIALLY, UP 4% YEAR-OVER-YEAR FOURTH QUARTER OPERATING MARGINS, EX-ITEMS, OF 12% FOURTH QUARTER GAAP EPS OF $0.15; EX-ITEMS, $0.22, DOWN 12% SEQUENTIALLY, UP 16% YEAR-OVER-YEAR FOURTH QUARTER FREE CASH FLOW OF $16.2 MILLION, UP OVER 50% SEQUENTIALLY DEBT LEVERAGE RATIO REDUCED TO 1.31, AND NET DEBT REDUCED BY $11.7 MILLION COMPANY REPURCHASED 264,982 SHARES OF COMMON STOCK, A VALUE OF $4.9 MILLION, DURING THE FOURTH QUARTER COMPANY ANNOUNCES Q1 2025 QUARTERLY DIVIDENDFULL YEAR REVENUE OF $523.8 MILLION, UP 3%FULL
HOUSTON, Jan. 3, 2025 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its fourth quarter 2024 conference call for investors and analysts at 7:30 a.m. CST / 8:30 a.m. EST on January 30, 2025. Larry Bruno, Chairman and CEO, Chris Hill, CFO, and Gwen Gresham, SVP Corporate Development and Investor Relations, will discuss financial and operational results. An earnings press release will be issued after market close on January 29, 2025 and may be accessed through the Company's website at www.corelab.com. To register for the listen-only webcast, log on to www.corelab.com at least fifteen minutes prior to the start of the call. For those not available to listen to the live webcast, a
THIRD QUARTER REVENUE OF $134.4 MILLION, UP 3% SEQUENTIALLY AND OVER 7% YEAR-OVER-YEARTHIRD QUARTER OPERATING INCOME OF $19.8 MILLION; EX-ITEMS, $18.2 MILLION, UP 11% SEQUENTIALLY AND 14% YEAR-OVER-YEAR THIRD QUARTER OPERATING MARGINS, EX-ITEMS, OF 14% UP 100 BPS SEQUENTIALLYTHIRD QUARTER GAAP EPS OF $0.25; EX-ITEMS, $0.25, UP 14% SEQUENTIALLY AND YEAR-OVER-YEARTHIRD QUARTER FREE CASH FLOW OF $10.4 MILLIONNET DEBT REDUCED BY $11.8 MILLION; DEBT LEVERAGE RATIO REDUCED TO 1.47COMPANY ANNOUNCES Q4 2024 QUARTERLY DIVIDENDHOUSTON, Oct. 23, 2024 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported third quarter 2024 revenue of $134,400,000. Core's op
4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
Citigroup downgraded Core Labs from Neutral to Sell and set a new price target of $21.00 from $22.00 previously
BofA Securities downgraded Core Labs from Neutral to Underperform and set a new price target of $21.50
BofA Securities upgraded Core Labs from Underperform to Neutral
FOURTH QUARTER REVENUE OF $129.2 MILLION, DOWN 4% SEQUENTIALLY AND UP SLIGHTLY YEAR-OVER-YEARFOURTH QUARTER OPERATING INCOME OF $14.2 MILLION; EX-ITEMS, $15.7 MILLION, DOWN 14% SEQUENTIALLY, UP 4% YEAR-OVER-YEAR FOURTH QUARTER OPERATING MARGINS, EX-ITEMS, OF 12% FOURTH QUARTER GAAP EPS OF $0.15; EX-ITEMS, $0.22, DOWN 12% SEQUENTIALLY, UP 16% YEAR-OVER-YEAR FOURTH QUARTER FREE CASH FLOW OF $16.2 MILLION, UP OVER 50% SEQUENTIALLY DEBT LEVERAGE RATIO REDUCED TO 1.31, AND NET DEBT REDUCED BY $11.7 MILLION COMPANY REPURCHASED 264,982 SHARES OF COMMON STOCK, A VALUE OF $4.9 MILLION, DURING THE FOURTH QUARTER COMPANY ANNOUNCES Q1 2025 QUARTERLY DIVIDENDFULL YEAR REVENUE OF $523.8 MILLION, UP 3%FULL
HOUSTON, Jan. 3, 2025 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its fourth quarter 2024 conference call for investors and analysts at 7:30 a.m. CST / 8:30 a.m. EST on January 30, 2025. Larry Bruno, Chairman and CEO, Chris Hill, CFO, and Gwen Gresham, SVP Corporate Development and Investor Relations, will discuss financial and operational results. An earnings press release will be issued after market close on January 29, 2025 and may be accessed through the Company's website at www.corelab.com. To register for the listen-only webcast, log on to www.corelab.com at least fifteen minutes prior to the start of the call. For those not available to listen to the live webcast, a
THIRD QUARTER REVENUE OF $134.4 MILLION, UP 3% SEQUENTIALLY AND OVER 7% YEAR-OVER-YEARTHIRD QUARTER OPERATING INCOME OF $19.8 MILLION; EX-ITEMS, $18.2 MILLION, UP 11% SEQUENTIALLY AND 14% YEAR-OVER-YEAR THIRD QUARTER OPERATING MARGINS, EX-ITEMS, OF 14% UP 100 BPS SEQUENTIALLYTHIRD QUARTER GAAP EPS OF $0.25; EX-ITEMS, $0.25, UP 14% SEQUENTIALLY AND YEAR-OVER-YEARTHIRD QUARTER FREE CASH FLOW OF $10.4 MILLIONNET DEBT REDUCED BY $11.8 MILLION; DEBT LEVERAGE RATIO REDUCED TO 1.47COMPANY ANNOUNCES Q4 2024 QUARTERLY DIVIDENDHOUSTON, Oct. 23, 2024 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported third quarter 2024 revenue of $134,400,000. Core's op
SCHEDULE 13G/A - Core Laboratories Inc. /DE/ (0001958086) (Subject)
8-K - Core Laboratories Inc. /DE/ (0001958086) (Filer)
SCHEDULE 13G - Core Laboratories Inc. /DE/ (0001958086) (Subject)